Related Experiment Video
Updated: Aug 19, 2025
10:33
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
Published on: December 17, 2021
2.8K
Topical interferon therapy in uveitic macular edema
Ankush Kawali1, Srinivasan Sanjay1, Ashwin Mohan2
1Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India.
Indian Journal of Ophthalmology
|December 1, 2022
Summary
Topical interferon alfa-2b eye drops are safe for uveitic macular edema (UME) but show limited efficacy. Long-term use may enhance effectiveness, warranting further research with dose adjustments and combination therapies.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Uveitic macular edema (UME) is a significant cause of vision loss.
- Current treatments for UME can be invasive or have systemic side effects.
Purpose of the Study:
- To evaluate the efficacy of topical interferon alfa-2b (IFN) in treating uveitic macular edema (UME).
Main Methods:
- A prospective, interventional case study involving 20 patients with UME.
- Topical IFN eye drops were administered four times daily (QID).
- Central macular thickness (CMT) was measured using optical coherence tomography (OCT) at baseline and follow-up.
Main Results:
- Mean CMT decreased significantly at 3 months post-treatment (P = 0.001).
- In eyes with baseline CMT ≥400 μm, a ≥50 μm decrease was observed in 5/6 eyes at ≥3 months.
- Complete UME resolution occurred in only three eyes; no adverse events were reported.
Conclusions:
- Topical IFN therapy is safe for UME but demonstrates limited short-term efficacy.
- Longer treatment durations may improve outcomes.
- Further research with dose modifications and combination therapies in homogeneous patient groups is recommended.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
520
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
520
01:28Angle Closure Glaucoma: Treatment
613
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
613
01:26Nephrotic Syndrome II : Assessment and Medical Management
16
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
16
01:25Glaucoma: Overview
685
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
685